Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A. Biernacka
Observed name:
Anna Biernacka
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0009-0008-9168-2700
Observed ORCID:
0009-0008-9168-2700
OpenAlex ID:
A5121109827
Standardized Upstream Processing of Ovarian Cancer Surgical Specimens for TIL-Oriented Cellular Workflows
2026
·
Anna Biernacka
, Joanna Kacperczyk-Bartnik
, et al.
·
Cancers
The Impact of Regulation (eu) 2024/1938 on Standards of Quality and Safety for Substances of Human Origin Intended for Human Application and Regulation (ec) No 1394/2007 on Advanced Therapy Medicinal Products on the Production of Tils Therapies in Cancer, With Particular Emphasis on Ovarian Cancer – Regulatory Implications for Poland
2026
·
J. Marynowska
, M. Gutek
, et al.
·
Cytotherapy
49P Correlation of cell counts, tumor mass, and histopathologic phenotype in serous ovarian carcinoma: Implications for TILs therapy development as an ATMP
2026
·
J. Marynowska
, M. Gutek
, et al.
·
ESMO Open
PDF
52eP Correlation of tumor size with cellular isolate yield in serous ovarian cancer as a predictive factor for ATMP manufacturing in TIL therapy
2026
·
Z. Usmial
, M. Gutek
, et al.
·
ESMO Open
PDF
653eP Innovative approach to tumor-infiltrating lymphocytes (TILs) production in ovarian cancer: Shortened manufacturing time and enhanced functional profile compared to the FDA-approved standard protocol for advanced melanoma
2025
·
J. Marynowska
, A. Biernacka
, et al.
·
Annals of Oncology
Brca1/2 Mutations, Hrd, and Tumor Size as Predictive Factors Influencing Til Expansion Efficiency and Clinical Response in Patients With Chemotherapy-resistant Ovarian Cancer
2025
·
M. Gutek
, A. Biernacka
, et al.
·
Cytotherapy
Show more works
View as search
Works count:
6
Citation count:
H-index:
I10-index:
Year
Topic
Type